{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T04:12:36Z","timestamp":1761883956219,"version":"build-2065373602"},"reference-count":31,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Reumatolog\u00eda Cl\u00ednica (English Edition)"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.reumae.2021.08.004","type":"journal-article","created":{"date-parts":[[2022,10,26]],"date-time":"2022-10-26T12:54:56Z","timestamp":1666788896000},"page":"523-530","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Real-world Effectiveness and Safety of JAK Inhibitors in Rheumatoid Arthritis: A Single-centre Study"],"prefix":"10.1016","volume":"18","author":[{"given":"Roxana","family":"Gonz\u00e1lez Mazar\u00edo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge Juan","family":"Frag\u00edo Gil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9","family":"Ivorra Cort\u00e9s","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Grau Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio Jos\u00e9","family":"Ca\u00f1ada Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis","family":"Gonz\u00e1lez Puig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosa Mar\u00eda","family":"Negueroles Albuixech","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Andr\u00e9s","family":"Rom\u00e1n Ivorra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.reumae.2021.08.004_bib0160","doi-asserted-by":"crossref","first-page":"18001","DOI":"10.1038\/nrdp.2018.1","article-title":"Rheumatoid arthritis","volume":"4","author":"Smolen","year":"2018","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.reumae.2021.08.004_bib0165","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/S0140-6736(10)60826-4","article-title":"Rheumatoid arthritis","volume":"376","author":"Scott","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.reumae.2021.08.004_bib0170","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2019-216655","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update","author":"Smolen","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reumae.2021.08.004_bib0175","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1136\/annrheumdis-2014-205489","article-title":"Methotrexate in combination with other DMARDs is not superior to methotrexate alone for remission induction with moderate-to-high-dose glucocorticoid bridging in early rheumatoid arthritis after 16 weeks of treatment: the CareRA trial","volume":"74","author":"Verschueren","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reumae.2021.08.004_bib0180","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1016\/S0140-6736(17)31472-1","article-title":"Pathogenetic insights from the treatment of rheumatoid arthritis","volume":"389","author":"McInnes","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.reumae.2021.08.004_bib0185","first-page":"519","article-title":"One year in review 2019: novelties in the treatment of rheumatoid arthritis","volume":"37","author":"Silvagni","year":"2019","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.reumae.2021.08.004_bib0190","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/nrrheum.2017.23","article-title":"The emerging safety profile of JAK inhibitors in rheumatic disease","volume":"13","author":"Winthrop","year":"2017","journal-title":"Nat Rev Rheumatol"},{"issue":"Suppl_1","key":"10.1016\/j.reumae.2021.08.004_bib0195","doi-asserted-by":"crossref","first-page":"i34","DOI":"10.1093\/rheumatology\/key287","article-title":"Growing evidence of the safety of JAK inhibitors in patients with rheumatoid arthritis","volume":"58","author":"Harigai","year":"2019","journal-title":"Rheumatology"},{"key":"10.1016\/j.reumae.2021.08.004_bib0200","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1002\/art.39953","article-title":"Baricitinib, methotrexate, or combination in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment","volume":"69","author":"Fleischmann","year":"2017","journal-title":"Arthr Rheumatol"},{"key":"10.1016\/j.reumae.2021.08.004_bib0205","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(17)31618-5","article-title":"Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b\/4, double-blind, head-to-head, randomized controlled trial","author":"Fleischmann","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.reumae.2021.08.004_bib0210","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1056\/NEJMoa1608345","article-title":"Baricitinib versus placebo or adalimumab in rheumatoid arthritis","volume":"376","author":"Taylor","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.reumae.2021.08.004_bib0215","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1136\/ard.2010.138461","article-title":"2010 rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative","volume":"69","author":"Aletaha","year":"2010","journal-title":"Ann Rheum Dis"},{"year":"2020","series-title":"Olumiant (Baricitinib) [prescribing information]","key":"10.1016\/j.reumae.2021.08.004_bib0220"},{"year":"2019","series-title":"Xeljanz (Tofacitinib) [prescribing information]","key":"10.1016\/j.reumae.2021.08.004_bib0225"},{"key":"10.1016\/j.reumae.2021.08.004_bib0230","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1136\/annrheumdis-2019-215458","article-title":"2018 update of the EULAR recommendations for the role of the nurse in the management of chronic inflammatory arthritis","volume":"79","author":"Bech","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reumae.2021.08.004_bib0235","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.reuma.2012.10.016","article-title":"Quality of care standards for nursing clinics in rheumatology","volume":"9","author":"Mu\u00f1oz Fern\u00e1ndez","year":"2013","journal-title":"Reumatol Clin"},{"key":"10.1016\/j.reumae.2021.08.004_bib0240","doi-asserted-by":"crossref","first-page":"119","DOI":"10.2147\/PPA.S192008","article-title":"Effect of patient education on medication adherence of patients with rheumatoid arthritis: a randomized controlled trial","volume":"13","author":"Taibanguay","year":"2019","journal-title":"Patient Prefer Adherence"},{"key":"10.1016\/j.reumae.2021.08.004_bib0245","first-page":"2116","article-title":"Spanish version of the Health Assessment Questionnaire (HAQ): reliability, validity and transcultural equivalency","volume":"20","author":"Esteve-Vives","year":"1993","journal-title":"J Rheumatol"},{"key":"10.1016\/j.reumae.2021.08.004_bib0250","first-page":"1401","article-title":"Standardizing assessment and reporting of adverse effects in rheumatology clinical trials II: the Rheumatology Common Toxicity Criteria v.2.0","volume":"34","author":"Woodwoth","year":"2007","journal-title":"J Rheumatol"},{"issue":"Suppl 10","key":"10.1016\/j.reumae.2021.08.004_bib0255","article-title":"Safety profile of Baricitinib for the treatment of rheumatoid arthritis up to 7 years: an updated integrated safety analysis","volume":"71","author":"Genovese","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.reumae.2021.08.004_bib0260","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1136\/annrheumdis-2018-eular.1733","article-title":"Tofacitinib, an oral janus kinase inhibitor, in the treatment of rheumatoid arthritis: safety and efficacy in open-label, long term extension studies over 9 years","volume":"77","author":"Wollenhaupt","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reumae.2021.08.004_bib0265","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1136\/annrheumdis-2016-210457","article-title":"Long-term safety of Tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials","volume":"76","author":"Cohen","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reumae.2021.08.004_bib0270","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1093\/rheumatology\/kez087","article-title":"A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis","volume":"58","author":"Bechman","year":"2019","journal-title":"Rheumatology"},{"key":"10.1016\/j.reumae.2021.08.004_bib0275","doi-asserted-by":"crossref","first-page":"e000742","DOI":"10.1136\/rmdopen-2018-000742","article-title":"Treatment outcomes in patients with Seropositive Versus Seronegative Rheumatoid Arthritis in Phase III Randomised Clinical Trials of Tofacitinib","volume":"5","author":"Bird","year":"2019","journal-title":"RMD Open"},{"key":"10.1016\/j.reumae.2021.08.004_bib0280","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1007\/s40264-018-0651-5","article-title":"Thromboembolism with janus kinase (JAK) inhibitors for rheumatoid arthritis: how real is the risk?","volume":"41","author":"Scott","year":"2018","journal-title":"Drug Saf"},{"key":"10.1016\/j.reumae.2021.08.004_bib0285","first-page":"485","article-title":"Real-world experience with tofacitinib for the treatment of rheumatoid arthrtitis","volume":"37","author":"Caporali","year":"2019","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.reumae.2021.08.004_bib0290","doi-asserted-by":"crossref","first-page":"26","DOI":"10.3390\/jcm8101548","article-title":"Effectiveness tolerability, and safety of tofacitinib in rheumatoid arthritis: a retrospective analysis of real-world data from the St. Gallen and Aarau Cohorts","volume":"8","author":"Mueller","year":"2019","journal-title":"J Clin Med"},{"key":"10.1016\/j.reumae.2021.08.004_bib0295","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s13075-018-1539-6","article-title":"Effectiveness and safety of tofacitinib in rheumatoid arthritis: a cohort study","volume":"20","author":"Machado","year":"2018","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.reumae.2021.08.004_bib0300","doi-asserted-by":"crossref","DOI":"10.1007\/s10067-020-05021-7","article-title":"Real-world evaluation of effectiveness, persistence, and usage patterns of tofacitinib in treatment of rheumatoid arthritis in Australia","author":"Bird","year":"2020","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.reumae.2021.08.004_bib0305","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s00393-020-00796-1","article-title":"Comparative efficacy and safety of tofacitinib, baricitinib, upadacitinib, and filgotinib in active rheumatoid arthritis refractory to biologic disease-modifying antirheumatic drugs","volume":"80","author":"Lee","year":"2021","journal-title":"Z Rheumatol"},{"key":"10.1016\/j.reumae.2021.08.004_bib0310","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1002\/acr.24596","article-title":"2021 American College of Rheumatology Guideline for the treatment of rheumatoid arthritis","volume":"73","author":"Fraenkel","year":"2021","journal-title":"Arthritis Care Res (Hoboken)"}],"container-title":["Reumatolog\u00eda Cl\u00ednica (English Edition)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2173574322001502?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2173574322001502?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T03:01:31Z","timestamp":1761879691000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2173574322001502"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":31,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["S2173574322001502"],"URL":"https:\/\/doi.org\/10.1016\/j.reumae.2021.08.004","relation":{},"ISSN":["2173-5743"],"issn-type":[{"type":"print","value":"2173-5743"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world Effectiveness and Safety of JAK Inhibitors in Rheumatoid Arthritis: A Single-centre Study","name":"articletitle","label":"Article Title"},{"value":"Reumatolog\u00eda Cl\u00ednica (English Edition)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.reumae.2021.08.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Espa\u00f1a, S.L.U. and Sociedad Espa\u00f1ola de Reumatolog\u00eda y Colegio Mexicano de Reumatolog\u00eda. All rights reserved.","name":"copyright","label":"Copyright"}]}}